Swarovsky B, Wolf M, Havemann K, Arnold R
Abteilung für Gastroenterologie und Stoffwechsel, Philipps-Universität, Marburg, BRD.
Oncology. 1993 Jul-Aug;50(4):226-9. doi: 10.1159/000227184.
Experimental evidence and preliminary clinical data suggest a responsiveness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists. In this study, we investigated the effect of the antiestrogen tamoxifen and the antiandrogen cyproterone acetate in combination with the LH-RH agonist buserelin in 9 patients with unresectable pancreatic adenocarcinoma. In all patients the disease was progressive under this therapeutic regimen. In conclusion, complete androgen blockade and antiestrogens in combination with LH-RH agonist cannot be recommended in patients with widespread pancreatic adenocarcinoma.
实验证据和初步临床数据表明，胰腺腺癌对性激素和促黄体生成素释放激素（LH-RH）激动剂有反应。在本研究中，我们调查了抗雌激素他莫昔芬和抗雄激素醋酸环丙孕酮联合LH-RH激动剂布舍瑞林对9例无法切除的胰腺腺癌患者的疗效。在所有患者中，该治疗方案下疾病均进展。总之，对于广泛胰腺腺癌患者，不推荐联合使用完全雄激素阻断和抗雌激素与LH-RH激动剂。
